ClinicalTrials.gg
RecruitingNCT07598825MERCURYUpdated Nov 3, 2026

A Trial of Inebilizumab in Participants With Autoimmune Hepatitis

A Phase 3 interventional study of Inebilizumab and Placebo in Autoimmune Hepatitis and AIH, sponsored by Amgen. Recruiting at 36 sites in 8 countries. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Updated Nov 3, 2026Now RecruitingFirst sites in 6 new countries+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Hepatitis, Autoimmune with a site in China — 3 open to participants now, 3 under way, 1 of them phase 3. Hepatitis, Autoimmune · China.

Planned enrollment
Largest of 10
180 · median 74
Started
2026
the only one that year
Phase 3
2 of 16
1 open now
Registered
16th of 16
by date
Lead sponsor
1 of 16
Amgen

Among the 16 studies in Hepatitis, Autoimmune with a site in China, this one has the largest planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2026, is one of 2 in phase 3, and was the 16th registered.

Hepatitis, Autoimmune

82 studies on the registry are indexed under Hepatitis, Autoimmune; 24 are open to participants now.

Browse Hepatitis, Autoimmune studies →

Open to participants now

3 of the 16 studies in Hepatitis, Autoimmune with a site in China are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 16 Hepatitis, Autoimmune studies recruiting now, 9 (56%) set no upper age limit and 4 (25%) stop at 75 or younger; 8 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Hepatitis, Autoimmune with a site in China, or all of them as a file.
02

Study summary

The main objectives of this trial are to evaluate the safety and tolerability of inebilizumab in participants with autoimmune hepatitis (AIH) (Part 1) and to evaluate the efficacy of inebilizumab on AIH disease activity and glucocorticoid (GC) use in the management of AIH (Part 2).

Read the detailed description

This study will consist of a screening period (up to 56 days), a randomized controlled treatment period (78 weeks), an optional open label period (OLP) up to 78 weeks (or until potential availability of the marketed drug) for eligible participants who complete the treatment period, and a safety follow-up (SFU) period up to 78 weeks.

The randomized controlled treatment period will be divided in 2 parts, a phase 2 dose confirmation and safety part (Part 1) and an efficacy evaluating phase 3 (Part 2). Part 1 will conclude when the last Part 1 participant has had the opportunity to complete the Week 26 visit. Part 2 will begin without pausing enrollment; the same randomization ratio and study procedures are maintained.

03

Conditions studied

  • Autoimmune Hepatitis
  • AIH

Browse trials for

Keywords

  • Autoimmune hepatitis
  • AIH
  • Inebilizumab
  • AMG 335
04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed .
  • Age ≥ 18 years or legal adult age within the country, whichever is older and \< 75 years at the time of signing the informed consent.
  • Participants must have either inadequate response to at least 9 months of SOC or are intolerant to SOC within 6 months of screening. Inadequate response to SOC treatment is defined as ≥ 2 (ULN) at screening after at least 9 months of SOC, including prednisone (or equivalent) > 5 mg/day and at least one conventional sparing agent at guideline-concordant target or highest appropriate dose, that is azathioprine (AZA) or 6-mercaptopurine (6-MP) at appropriate weight-based dosing (typically up to 2 mg/kg/day AZA or 1 mg/kg/day 6-MP) or mycophenolate (MMF) up to 2 g/day, as judged appropriate by the investigator and documented in the medical record.

Intolerance to SOC treatment is defined as any adverse event related to treatment that results in discontinuation of the medication or prevents dose optimization necessary to achieve or maintain biochemical response, as determined by the Principal Investigator (PI). Intolerance applies to GCs, AZA, 6-MP, or MMF. Presence of one or more clinically significant adverse effects attributed to SOC include but not limited to side effects that, in the opinion of the investigator, compromise participant's safety or quality of life, exacerbate comorbid conditions, or render continued use medically inappropriate.

  • Participants with disease activity at screening as follows: ALT ≥ 2 x ULN to ≤ 7 x ULN. ALT ULN values will be gender specific.
  • Participant must have a proven definitive diagnosis of AIH according to simplified diagnostic criteria (score ≥ 7). Liver biopsy should be obtained within 90 days prior to randomization. Participants must have a mHAI score ≥ 5 in the biopsy.
  • Participant should be on:

    • No increase in GC dose during the 28 days immediately preceding whichever biopsy is designated as the baseline sample-historical or screening-and the dose post biopsy must remain unchanged through the day of randomization AND
    • Stable maximum tolerated doses of AZA or 6-MP for at least 12 weeks prior to screening (baseline) liver biopsy until randomization and during the entire treatment period unless dose reduction is deemed necessary for safety or tolerance reasons OR
    • Stable maximum tolerated doses of MMF/mycophenolic acid (MPA) for at least 12 weeks prior to screening (baseline) liver biopsy until randomization and during the entire treatment period unless dose reduction is deemed necessary for safety or tolerance reasons.
  • Participants must use protocol-specified during treatment and for an additional 6 months after the last dose of trial intervention.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of definitive overlap liver or rheumatologic syndrome with autoimmune hepatitis (eg, AIH + primary biliary cholangitis [PBC], AIH + primary sclerosing cholangitis [PSC], AIH related to Systemic Lupus Erythematosus, etc) where established overlap criteria are met.
  • Acute liver failure (ALF) at screening (e.g., acute hepatic dysfunction with coagulopathy and any degree of encephalopathy) in the investigator's judgment.
  • Participant has known history of:

    • Allergy or reaction to any component of inebilizumab formulation or history of anaphylaxis to any human gamma globulin therapy.
    • Allergy to or intolerance of protocol-required treatment, including medications for prophylaxis of infusion reactions (antipyretic such as paracetamol/acetaminophen or equivalent, diphenhydramine or equivalent, and methylprednisolone or equivalent).
  • Active or history of malignancy that was active within the last 10 years, except as follows:

    • In situ carcinoma of the cervix treated with apparent success with curative therapy for > 12 months prior to screening
    • Curatively treated breast ductal carcinoma in situ
    • Cutaneous basal cell or squamous cell carcinoma treated with apparent success with curative therapy for > 12 months prior to screening
    • Prostate cancer treated with radical prostatectomy or radiation therapy with curative intent > 3 years prior to screening and without known recurrence or current treatment
    • Thyroid cancer for which complete surgical resection has been performed within 5 years with well-differentiated histology (papillary thyroid carcinoma or follicular thyroid carcinoma) and there is no evidence of active disease.
  • Known positive test for (HIV) infection. Evidence of HIV infection or positive for HIV antibodies at initial screening or current acquired, common variable or inherited, primary or secondary immunodeficiency.
  • Presence or history of viral hepatitis infection:

    • Positive test for, or prior treatment for, . A positive test for hepatitis B is detection of either:

      • Positive for hepatitis B surface antigen (HBsAg) OR
      • anti-HBc
    • Participants with a history of or current virus (HCV) infection, even those considered to be cured.
  • Active tuberculosis (TB) or latent TB with no documented history of adequate treatment per local SOC.
  • Positive test for TB during screening is defined as positive QuantiFERON® test. At screening, all participants must be tested with an interferon-γ release assay (IGRA) (QuantiFERON®).
  • History of > 1 episode of herpes zoster (any grade) and/or any other definite or probable opportunistic infection in the 12 months prior to screening.
  • Estimated \< 45 mL/min/1.73 m\^2 using chronic kidney disease epidemiology (CKD-EPI) 2021 formula.
  • Blood tests at screening that meet any of the following criteria:

    • \< 7.5 g/dL
    • Neutrophils \< 1200/mm\^3
    • \< 150 x 10\^9/L
    • (INR) > 1.3
    • cluster of differentiation 19 (CD19)+ B cells at screen \< 40 cells/µL; an exclusionary value may be repeated.
    • Serum albumin level \< 35 g/L
    • Direct (BIL) in serum >
    • Total BIL ≥ 2.0 mg/dL
    • ALP > 1.5 x ULN
    • > 7 x ULN Note: Participants with baseline cytopenia (where permitted) may be enrolled if, in the Investigator's judgment, the cytopenia derives from an alternative to AIH condition (eg, medication effect, nutritional deficiency, anemia of chronic disease etc).
  • Active, infection at the time of randomization ( product administration may be delayed until recovery, if within screening window, otherwise participant may be rescreened).
  • History or evidence of uncontrolled alcohol use disorder (AUD), defined as participants who have a history of significant alcohol consumption, ie, consumption of >2 units/day for males and >1 unit/day for females, sustained for ≥ 3 consecutive months.
  • History of recurrent significant infections (eg, requiring hospitalization or IV antibiotics) within the past 12 months.
  • Major surgery within 8 weeks before screening.
  • Severe cardiovascular, respiratory, endocrine, gastrointestinal, hematological, neurological, psychiatric, or systemic disorder, or any other condition that, in the opinion of the Investigator, would place the participant at unacceptable risk of complications, interfere with evaluation of the Investigational product or confound the interpretation of participant safety or trial results.
  • Known immunodeficiency disorder.
  • Participants with moderate-to-severe metabolic dysfunction-associated steatohepatitis (MASH) on screening/baseline liver , defined by central pathology review as steatosis grade ≥ 2 with lobular inflammation ≥ 1, and hepatocellular ballooning ≥ 1.
  • Participants with decompensated cirrhosis, either historical or present at screening defined by:

    • Histologic cirrhosis on screening or prior liver biopsy (fibrosis stage F4 / Ishak 5-6), and
    • Prior hepatic decompensation or B-C.
    • Child-Pugh category A at screening, without a history of prior hepatic decompensation (ascites, encephalopathy, variceal bleeding, spontaneous bacterial peritonitis [SBP], hepatorenal syndrome [HRS], acute-on-chronic liver failure, or progression to decompensated cirrhosis), is eligible.
  • Participant with a history of drug-induced liver injury (DILI), regardless of offending agent.
  • Receipt of any biologic B cell-depleting therapy (eg, rituximab, ocrelizumab, obinutuzumab, ofatumumab, inebilizumab, ianalumab) in the 6 months prior to screening.
  • Receipt of non-depleting B cell-directed therapy (eg, belimumab), abatacept, or other biologic immunomodulatory agent within 6 months prior screening.
  • Receipt of tumor necrosis factor (TNF) inhibitors (eg, infliximab, adalimumab) within 6 months prior screening.
  • Receipt of agents such as calcineurin inhibitors (tacrolimus, cyclosporin except eye drops), methotrexate, mammalian target of rapamycin inhibitors (eg, everolimus) within 6 weeks prior screening.
  • Receipt of any investigational agent \< 12 weeks or \< 5 half-lives of the drug (whichever is longer) prior to screening.
  • History of inability to be tapered off of GC therapy due to adrenal insufficiency or due to recurrent or prolonged systemic therapy for any medical condition other than AIH (eg, severe steroid-dependent asthma) according to PI.
  • All vaccines are prohibited within 4 weeks before the first dose of trial treatment.

    • Participants are recommended to be administered vaccines at least 4 weeks prior to dosing in accordance with local recommendations prior to enrollment to allow for adequate immune response.
  • Required regular use of medications with known hepatotoxicity.
  • Current use of:

    • GCs (prednisone > 20 mg/day, or equivalent dose of other GCs)
    • AZA > 2 mg/kg/day
    • 6-MP > 1 mg/kg/day
    • MMF > 2 g/day or MPA > 1440 mg/day.
  • Any concomitant immunosuppressive treatment, alone or in combination with GCs, except for AZA, 6-MP, MMF, and MPA.
  • Undetectable levels of 6-thioguanine nucleotides (6-TGN) or MPA during screening unless participants are not on AZA or MMF/MPA due to intolerance per protocol.
  • No new Herbal and Dietary Supplements (HDS) products for 4 weeks prior to first dose of inebilizumab.
  • Currently receiving a trial intervention, or less than 30 days or 5 half-lives if known (whichever is later) since ending a trial intervention in another investigational device or drug trial.
  • Unable to safely undergo a liver biopsy.
  • Participant unlikely to be able to complete all protocol-required procedures, restrictions and requirements, in the judgment of the individual and investigator.
  • History or evidence of any other clinically significant disorder, condition, or disease that, in the opinion of the investigator, would pose a risk to participant safety.
  • Currently pregnant (confirmed with positive pregnancy test) or breastfeeding or planning to become pregnant, donate eggs, or breastfeed while on trial until an additional 6 months after the last dose of inebilizumab (if applicable) with highest teratogenic risk.
  • Participants of with a positive pregnancy test assessed by serum pregnancy test at screening and a urine pregnancy test at Day 1 visit.
  • Participant unwilling to abstain from donating blood or plasma during the trial.

In order for participants to continue to OLP, they must:

  • Have completed the randomized controlled treatment period Week 78 visit and received all doses or not discontinued investigational product for any of the following reasons:

    • Anaphylaxis or a serious reaction that occurred within 7 days after IV dosing and cannot be attributed to another known allergen exposure.
    • Any adverse events or significant laboratory abnormality that, in the opinion of the investigator, Amgen, or Data Monitoring Committee (DMC), warrants discontinuation of dosing.
    • Any life-threatening (grade 4) infection.
    • Any event of sepsis or febrile neutropenia.
    • Any infection listed as either a definite or probable opportunistic infection.
    • Any grade 3 infusion related reactions (IRR).
    • Any grade 4 serious adverse events.
    • Pregnancy or a decision to become pregnant.
    • Malignancy.
    • \< 800 cells/µL confirmed by repeat testing.
    • Determination that the participant was ineligible for trial participation and continuation of investigational product could pose a safety risk to the participant in the judgment of the investigator or the sponsor.
    • Significant noncompliance with the trial protocol, as judged by the investigator or Amgen.
  • Receive dose 1 in the OLP within the window of 7 days after the randomized controlled treatment period Week 78 visit and only after the Week 78 biopsy has been completed.
  • Participants who meet protocol-defined early escape criteria and discontinue the RCP may enter the OLP, provided they have not discontinued investigational product for safety-related reasons that preclude further dosing.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Part 1: Inebilizumab

    Participants will receive inebilizumab as an intravenous (IV) infusion in addition to standard of care (SOC).

    Drug: Inebilizumab · Other: Standard of Care

  • Experimental
    Part 1: Placebo

    Participants will receive placebo as an IV infusion in addition to SOC.

    Drug: Placebo · Other: Standard of Care

  • Experimental
    Part 2: Inebilizumab

    Participants will receive Inebilizumab as an IV infusion in addition to SOC.

    Drug: Inebilizumab · Other: Standard of Care

  • Experimental
    Part 2: Placebo

    Participants will receive placebo as an IV infusion in addition to SOC.

    Drug: Placebo · Other: Standard of Care

Interventions

  • Inebilizumab will be administered as an IV infusion.

    Also known as: AMG 335

  • DrugPlacebo

    Placebo will be administered as IV infusion.

  • OtherStandard of Care

    Standard of Care

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants who Experienced Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs of Interest at Week 26

    Time frame: Up to Week 26

  2. Part 2: Number of Participants who Achieved Modified Histologic Activity Index (mHAI) ≤ 3 and Stable Prednisone Dose (or equivalent) ≤ 5 mg/day at Week 78

    Participants who met the two outcomes combined will be reported for this endpoint.

    Time frame: Week 78

Secondary outcomes

  1. Part 1: Number of Participants who Achieved Normal Alanine Aminotransferase (ALT) Levels at Week 26

    Time frame: Week 26

  2. Part 1: Change from Baseline in ALT Levels at Week 26

    Time frame: Baseline and Week 26

  3. Part 1: Maximum Serum Concentration (Cmax) of Inebilizumab

    Time frame: Up to Week 26

  4. Part 1: Area Under the Serum Concentration-time Curve (AUC) of Inebilizumab

    Time frame: Up to Week 26

  5. Part 1: Change from Baseline in Peripheral B Cell Counts at Week 26

    Time frame: Baseline and Week 26

  6. Part 2: Number of Participants who Achieved Sustained Normal ALT Levels and Stable Prednisone Dose (or equivalent) ≤ 5 mg/day by Week 78

    Sustained normal ALT levels is defined as achieving normal ALT levels in the 3 consecutive visits. Participants who met the two outcomes combined will be reported for this endpoint.

    Time frame: Week 78

  7. Part 2: Number of Participants who Achieved Normal ALT Levels, mHAI ≤ 3 and Stable Prednisone Dose (or equivalent) ≤ 5 mg/day at Week 78

    Participants who met the three outcomes combined will be reported for this endpoint.

    Time frame: Week 78

  8. Part 2: Number of Participants who Achieved Stable Prednisone Dose (or equivalent) ≤ 5 mg/day by Week 78

    Time frame: Week 78

  9. Part 2: Number of Participants who Achieved Normal ALT Levels and Stable Glucocorticoid (GC) Free (0 mg) by Week 78

    Participants who met the two outcomes combined will be reported for this endpoint.

    Time frame: Week 78

  10. Part 2: Time to Persistently Achieve Normal ALT Levels and Stable Prednisone (or equivalent) ≤ 5 mg/day Through Week 78

    Time to achieve normal ALT levels is defined as as the first occurrence of normal ALT levels in at least 2 consecutive visits through Week 78. Participants who met the two outcomes combined will be reported for this endpoint.

    Time frame: Up to Week 78

  11. Part 2: Change from Baseline in ALT Levels at Week 78

    Time frame: Baseline and Week 78

  12. Part 2: Change from Baseline in Immunoglobulin G (IgG) Levels at Week 78

    Time frame: Baseline and Week 78

  13. Part 2: Change from Baseline in Aspartate Aminotransferase (AST) Levels at Week 78

    Time frame: Baseline and Week 78

  14. Part 2: Change from Baseline in mHAI at Week 78

    Time frame: Baseline and Week 78

  15. Part 2: Number of Participants who Achieved Normal ALT and IgG Levels at Week 78

    Participants who met the two outcomes combined will be reported for this endpoint.

    Time frame: Week 78

  16. Part 2: Number of Participants who Achieved mHAI ≤ 3 at Week 78

    Time frame: Week 78

  17. Part 2: Number of Participants who Achieved Flare-free, Stable GC-free (0 mg) Normalization of ALT by Week 78

    Time frame: Week 78

  18. Part 2: Cumulative GC Dose per Participant for AIH

    Time frame: Up to Week 78

  19. Part 2: Number of Participants with Anti-drug Antibodies (ADA)

    Time frame: Up to Week 78

  20. Part 2: Cmax of Inebilizumab

    Time frame: Up to Week 78

  21. Part 2: AUC of Inebilizumab

    Time frame: Up to Week 78

  22. Part 2: Number of Participants who Experienced TEAEs, Serious TEAEs, and TEAEs of Interest

    Time frame: Up to Week 78

  23. Part 2: Change from Baseline of GC Toxicity Index Score at Week 78

    Time frame: Baseline and Week 78

07

Study locations

35 of 36 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this trial will be considered beginning 18 months after the trial has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this trial.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen trial/trials in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Dec 2026; primary completion for Jul 2031, 55 months later.

Start moved twice since we started tracking on Sep 25, 2026: Sep 2026 → Dec 2026, last on Nov 3, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2026
First posted
May 20, 2026
StartEst.
Dec 18, 2026was Sep 2026
Primary completionEst.
Jul 30, 2031
CompletionEst.
Feb 11, 2034
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 16, 2026
Sites
25 sites added, 1 site removed — first sites in Canada, Belgium, France, Germany, Hungary and 1 more
All 6 countries

Canada, Belgium, France, Germany, Hungary, Italy

. 11 sites changed recruiting status (11 now recruiting)
Show 11 sites
  • Applied Research Center of Arkansas · Little Rock, United Statesno status→Recruiting
  • Inland Empire Liver Foundation · Rialto, United Statesno status→Recruiting
  • Indiana University · Indianapolis, United Statesno status→Recruiting
  • Methodist Cardiovascular Consultants - Dallas · Dallas, United Statesno status→Recruiting
  • American Research Corporation · San Antonio, United Statesno status→Recruiting
  • The Second Hospital of Anhui Medical University · Hefei, Chinano status→Recruiting
  • Peking University First Hospital · Beijing, Chinano status→Recruiting
  • Beijing Friendship Hospital, Capital Medical University · Beijing, Chinano status→Recruiting
  • Peking Union Medical College Hospital · Beijing, Chinano status→Recruiting
  • The First Affiliated Hospital of Zhengzhou University · Zhengzhou, Chinano status→Recruiting
  • Renji Hospital Shanghai Jiaotong University School of Medicine · Shanghai, Chinano status→Recruiting
Show 25 added (11 China, 7 United States, 2 Canada, 1 Belgium, 1 France, 1 Germany, 1 Hungary, 1 Italy)
  • Amicis Research Center · Valencia, United States
  • Floridian Clinical Research LLC · Miami Lakes, United States
  • McGIll University Health Centre Glen Site · Montreal, Canada
  • The Second Affiliated Hospital of Chongqing Medical University · Chongqing, China
  • Union Hospital Tongji Medical College Huazhong University of Science and Technology · Wuhan, China
  • The Second Hospital of Nanjing · Nanjing, China
  • The Fifth Peoples Hospital of Suzhou · Suzhou, China
  • The First Bethune Hospital of Jilin University · Changchun, China
  • West China Hospital Sichuan University · Chengdu, China
  • Mayo Clinic Jacksonville · Jacksonville, United States
  • Florida Research Institute · Largo, United States
  • Mayo Clinic Rochester · Rochester, United States
  • University of Pennsylvania · Philadelphia, United States
  • Medical University of South Carolina · Charleston, United States
  • Universitair Ziekenhuis Leuven · Leuven, Belgium
  • Centre de Recherche du Centre Hospitalier de l Universite de Montreal · Montreal, Canada
  • Beijing Youan Hospital, Capital Medical University · Beijing, China
  • Mengchao Hepatobiliary Hospital of Fujian Medical University · Fuzhou, China
  • Nanjing Drum Tower Hospital · Nanjing, China
  • Tianjin Medical University General Hospital · Tianjin, China
  • Tianjin First Central Hospital · Tianjin, China
  • Hôpital Saint Antoine · Paris, France
  • Universitaetsklinikum Jena · Jena, Germany
  • Obudai Egeszsegugyi Centrum Kft · Zalaegerszeg, Hungary
  • IRCCS Istituto Clinico Humanitas · Rozzano, Italy
Show 1 removed
  • Amicis Research Center · Northridge, United States
across 2 updates, Oct 16, 2026 – Nov 3, 2026
Start date
Sep 7, 2026→Dec 18, 2026
moved 2 times, Oct 16, 2026 – Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    16 sites added — first sites in Belgium, France, Germany, Hungary and Italy
    Show 16 added (5 United States, 5 China, 1 Belgium, 1 Canada, 1 France, 1 Germany, 1 Hungary, 1 Italy)
    • Mayo Clinic Jacksonville · Jacksonville, United States
    • Florida Research Institute · Largo, United States
    • Mayo Clinic Rochester · Rochester, United States
    • University of Pennsylvania · Philadelphia, United States
    • Medical University of South Carolina · Charleston, United States
    • Universitair Ziekenhuis Leuven · Leuven, Belgium
    • Centre de Recherche du Centre Hospitalier de l Universite de Montreal · Montreal, Canada
    • Beijing Youan Hospital, Capital Medical University · Beijing, China
    • Mengchao Hepatobiliary Hospital of Fujian Medical University · Fuzhou, China
    • Nanjing Drum Tower Hospital · Nanjing, China
    • Tianjin Medical University General Hospital · Tianjin, China
    • Tianjin First Central Hospital · Tianjin, China
    • Hôpital Saint Antoine · Paris, France
    • Universitaetsklinikum Jena · Jena, Germany
    • Obudai Egeszsegugyi Centrum Kft · Zalaegerszeg, Hungary
    • IRCCS Istituto Clinico Humanitas · Rozzano, Italy
    Start date Oct 13, 2026→Dec 18, 2026
    + 1 other change: verification date
  2. Oct 16, 2026
    Not yet recruiting→Recruiting
    9 sites added, 1 site removed — first site in Canada. 11 sites changed recruiting status (11 now recruiting)
    Show 11 sites
    • Applied Research Center of Arkansas · Little Rock, United Statesno status→Recruiting
    • Inland Empire Liver Foundation · Rialto, United Statesno status→Recruiting
    • Indiana University · Indianapolis, United Statesno status→Recruiting
    • Methodist Cardiovascular Consultants - Dallas · Dallas, United Statesno status→Recruiting
    • American Research Corporation · San Antonio, United Statesno status→Recruiting
    • The Second Hospital of Anhui Medical University · Hefei, Chinano status→Recruiting
    • Peking University First Hospital · Beijing, Chinano status→Recruiting
    • Beijing Friendship Hospital, Capital Medical University · Beijing, Chinano status→Recruiting
    • Peking Union Medical College Hospital · Beijing, Chinano status→Recruiting
    • The First Affiliated Hospital of Zhengzhou University · Zhengzhou, Chinano status→Recruiting
    • Renji Hospital Shanghai Jiaotong University School of Medicine · Shanghai, Chinano status→Recruiting
    Show 9 added (6 China, 2 United States, 1 Canada)
    • Amicis Research Center · Valencia, United States
    • Floridian Clinical Research LLC · Miami Lakes, United States
    • McGIll University Health Centre Glen Site · Montreal, Canada
    • The Second Affiliated Hospital of Chongqing Medical University · Chongqing, China
    • Union Hospital Tongji Medical College Huazhong University of Science and Technology · Wuhan, China
    • The Second Hospital of Nanjing · Nanjing, China
    • The Fifth Peoples Hospital of Suzhou · Suzhou, China
    • The First Bethune Hospital of Jilin University · Changchun, China
    • West China Hospital Sichuan University · Chengdu, China
    Show 1 removed
    • Amicis Research Center · Northridge, United States
    Start date Sep 7, 2026→Oct 13, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07598825
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
May 20, 2026
Start date
Dec 18, 2026 (estimated)
Primary completion
Jul 30, 2031 (estimated)
Completion
Feb 11, 2034 (estimated)
Last update
Nov 3, 2026

Study contacts

Amgen Call Center
Contact
medinfo@amgen.com
866-572-6436
MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inebilizumab

Start the discussion